Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03.
Year: 2024
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Erika P. Hamilton, Sara A. Hurvitz, Seock-Ah Im, Hiroji Iwata, Giuseppe Curigliano, Sung-Bae Kim, Joanne Wing-Yan Chiu, Jose Luiz Pedrini, Wei Li, Kan Yonemori, Giampaolo Bianchini, Sherene Loi, Giuliano Santos Borges, Xian Wang, Thomas Bachelot, Shunsuke Nakatani, Shahid Ashfaque, Zhengkang Liang, Anton Egorov, Javier Cortes
Institutions: Sarah Cannon, University of Washington, Fred Hutch Cancer Center, Seoul National University, Seoul National University Hospital, Aichi Cancer Center Hospital, University of Milan, European Institute of Oncology, Asan Medical Center, University of Ulsan, Queen Mary Hospital, University of Hong Kong, First Hospital of Jilin University, National Cancer Center Hospital, Vita-Salute San Raffaele University, Peter MacCallum Cancer Centre, IRCCS Ospedale San Raffaele, Sir Run Run Shaw Hospital, Zhejiang University, Centre Léon Bérard, Daiichi-Sankyo (Japan), Daiichi Sankyo (United States), Hospital Quirónsalud Barcelona, IDCQ Hospitales y Sanidad, S.L.U.
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4399323636